Venus Remedies Limited, a global pharmaceutical company, has received Good Manufacturing Practices (GMP) certification from the Ministry of Health of Moldova for its antibiotic-carbapenem manufacturing facility. Carbapenems, recognized as a class of broad-spectrum antibiotics, are instrumental in treating severe infections.

“In 2024, Venus Remedies established itself as one of the top five pharmaceutical exporters from India to Moldova. The GMP certification for Venus Remedies’ facility is expected to unlock further opportunities in the Moldovan market, contributing anticipated sales of USD 300,000 in 2025 and approximately USD 700,000–$800,000 in 2026," said Saransh Chaudhary, President, Global Critical Care, Venus Remedies, and CEO, Venus Medicine Research Centre.  

The European antibiotics market was valued at USD 11,561.2 million in 2019 and is projected to reach USD 13,529.8 million by 2027, growing at a CAGR of 1.9 percent from 2020 to 2027. Specifically, the Europe carbapenem market generated revenue of USD 1,061.4 million in 2022 and is expected to grow at a CAGR of 4 percent from 2023 to 2030.

Aditi Chaudhary, President of International Business at Venus Remedies, said, “Antibiotics, along with oncology and hormones, rank among the leading therapy areas for Indian pharmaceutical exports to Moldova. This approval will ensure access to effective and dependable antibiotics for healthcare providers and patients in the country.”

In Moldova, the pharmaceutical market is expected to demonstrate an annual growth rate (CAGR 2024–2029) of 3.22 percent, reaching a market volume of USD 83.32 million by 2029.